Symposium: Prediction of Response to Neuroleptic Drug Therapy in Schizophrenia

Davis J.M. , Schaffer C.B. . Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70–87.

Strauss J.C. , Carpenter W.C. Prediction of outcome in schizophrenia III; five-year outcome and its predictors. Arch Gen Psychiatry 1977; 34: 159–163.

Gift T.E. , Strauss J.S. . Schizophrenia: affect and outcome. Am J Psychiatry 1980; 137: 580–585.

Seeman M.V. Schizophrenic men and women require different treatment programmes. J Psychiat Treat Evaluation 1983; 5: 143–148.

Seeman M.V. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 1983; 24: 125–128.

Van Praag H.M. The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenia. Br J Psychiatry 1977; 130: 463–474.

Davis M.M. , Erickson S. , Dekirmenjian H. Plasma levels of antipsychotic drugs and clinical response. In: Upton M.A. , Di Mascio A. , Killiam K.F. eds. Psychopharmacology: a generation of progress. New York: Raven Press, 1978.

May P.R.A. , van Putten T. Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 1978; 35: 1081–1087.

Braun G. , Poos G. , Sondijn W. Distribution, excretion and metabolism of neuroleptics of butyrophenone type. Europ J Pharm 1967; 1: 58–62.

Extein I. , Augusthy K.A. . Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 1982; 18: 156–158.

Itil T.M. , Marasa J. . Computerized EEG: predictor of outcome in schizophrenia. J Nerv Ment Dis 1975; 160: 188–203.